Autolus Ltd.

Autolus is at the forefront of a revolution in cancer treatment. Chimeric Antigen Receptor (CAR) T cell therapies have been shown to be effective in some blood cancer and may have wide applications as a cancer treatment, with the potential for cure in some patients. The Company is a global leader in T-cell programming and manufacturing technology. Working in partnership with physicians and other healthcare providers, Autolus extracts immune cells from patients, equips them with a receptor that targets the cancer cell and infuses them back into the patient in order to develop therapies which the Company believes will offer cancer patients substantial benefits over the existing standard of care.